| 翁雪燕,陈绵雄,熊 青,符兰芳,林 慧.口服降糖药和胰岛素对不同临床分期糖尿病视网膜病变病情进程的影响[J].现代生物医学进展英文版,2017,17(14):2711-2713. |
| 口服降糖药和胰岛素对不同临床分期糖尿病视网膜病变病情进程的影响 |
| Effects of Oral Medications and Insulin on Disease Progress of Different Clinical Stages of Diabetic Retinopathy |
| Received:July 31, 2016 Revised:August 30, 2016 |
| DOI：10.13241/j.cnki.pmb.2017.14.027 |
| 中文关键词: 糖尿病视网膜病变 药物控制 胰岛素控制 病变进展 |
| 英文关键词: Diabetic retinopathy Drug control Insulin control Lesion progress |
| 基金项目:海南省自然科学基金项目（807092） |
|
| Hits: 395 |
| Download times: 202 |
| 中文摘要: |
| 摘要 目的：探讨降糖药物和胰岛素控制血糖对不同临床分期糖尿病视网膜病变进程的影响。方法：收集糖尿病伴有视网膜病变的患者78例。采用随机表法，将糖尿病视网膜病变患者分为药物控制血糖组和胰岛素控制组，药物治疗组38例，胰岛素治疗组40例，使血糖达到控制标准。评价干预前后患者血清C肽、糖化血红蛋白、胰岛素抵抗指数，以及糖尿病视网膜病变分级。结果：药物控制组治疗前后2 h CP、以及糖化血红蛋白测定差异无统计学意义(p>0.05)。胰岛素组治疗前后，血清空腹C肽、2 h CP差异有统计学意义(p<0.05)；而糖化血红蛋白、胰岛素抵抗指数差异无统计学意义(p>0.05)。药物组治疗前Ⅰ期、Ⅱ期、Ⅲ期、Ⅳ期、Ⅴ期、Ⅵ期病例数和治疗后相比，差异有统计学意义(p<0.05)，视网膜病变分级程度明显增高。胰岛素组治疗前Ⅰ期、Ⅱ期、Ⅲ期、Ⅳ期、Ⅴ期、Ⅵ期病例数和治疗后相比，差异有统计学意义(p<0.05)。药物组和胰岛素组间视网膜病变分级差异无统计学意义(p>0.05)；治疗后差异有统计学意义(p<0.05)。结论：胰岛素能够提高糖尿病患者血清C肽，降低胰岛素抵抗，和药物控制血糖相比，能够延缓糖尿病视网膜病变的进展。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the influences of hypoglycemic drugs and insulin to keep blood sugar under control on the procession of diabetic retinopathy in different clinical stages. Methods: From January 2014 to February 2015, 78 cases of diabetes associated with retinopathy patients were collected. By random table method, the patients with diabetic retinopathy were divided into drug group (38 cases) and insulin group (40 cases), to control their blood sugar levels to standards. Evaluate the levels of serum C peptide, glycosylated hemoglobin, insulin resistance index, and diabetic retinopathy grades of patients before and after the intervention. Results: There were no statistically significant differences in CP and glycosylated hemoglobin levels in the drug group at 2 h before and after treatment (p > 0.05). In Insulin group, there was statistically significant difference in fasting serum c-peptide and 2h CP before and after treatment (p < 0.05), while the glycosylated hemoglobin and insulin resistance index had no statistical difference (p > 0.05). In drug group, the numbers of cases in stage Ⅰ, Ⅱ, Ⅲ, Ⅳ, Ⅴ or Ⅵ before treatment were statistically different from those after treatment (p < 0.05), and retinopathy grade increased significantly. In insulin group, the numbers of cases in stage Ⅰ, Ⅱ, Ⅲ, Ⅳ, Ⅴ or Ⅵ before treatment were also statistically different from those after treatment (p < 0.05). Before treatment, the retinopathy grade differences between drug group and insulin group had no statistical significance (p > 0.05), but thedifference was statistically significant after treatment (p < 0.05). Conclusion: Insulin can improve the serum C peptide and reduce the insulin resistance of diabetic retinopathy patients. Compared with medications to control blood sugar, insulin can delay the progress of diabetic retinopathy. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
